Where we’ve been

The beginning | Biomatrix discovery

While developing long-term implants, the Company recognized the many advantages of matching an implant’s composition to the native tissue surrounding the implant site. The Company also recognized that these biomatrix materials exhibited no adverse effects. As a result, the Company began pursuing the development of several new product lines utilizing these new proprietary biomatrix materials.

2004 | Manufacturing advances

In an effort to scale manufacturing, the Company developed an improved manufacturing process, which also produced a superior biomaterial that inherently possessed thermoplastic properties. 

2005-2013 | $5.5M Awarded

The National Institutes of Health awarded the Company a series of grants totaling $5.5M for the development of vascular grafts and other devices. The work derived from the vascular graft grant produced the completion of pre-clinical testing required for a FDA small diameter vascular graft clinical trial. 

2006 | Safety & efficacy

After the Company determined that the easiest path to validate the safety and efficacy of the new biomatrix implant material for human use was as a dermal filler, the FDA approved the Company’s IDE to conduct a Randomized, Double-Blind, Multicenter Dermal Filler Clinical Trial, in which the Company’s CosmetaLife dermal filler was injected into one side of each trial participant’s face and Restylane (Control) was injected into the other side. The blinded participants scored each naso-labial fold using the Global Aesthetic Improvement Scale and preferred the Company’s product at all trial time points. 

2012 | Patent achieved

The United States Patent and Trademark Office issued the Company US Patent 8,153,591, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof.” Originally filed in 2004, this key patent included ninety-three claims focused on many aspects of our biomatrix materials, manufacturing processes and numerous methods of use. 

2017-Present | Growth & commercialization

PetVivo merged with Gel-Del Technologies, Inc., which is now a wholly owned subsidiary of the Company, PetVivo Holdings, Inc.

Present | Spryng™ with OsteoCushion™ Technology

The first commercialization of the biomatrix technology is launched as Spryng™ with OsteoCushion™ Technology in the animal healthcare market for the management of lameness issues, joint pain and osteoarthritis.